# 2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.

> **NCT00223977** · PHASE2,PHASE3 · COMPLETED · sponsor: **Watson Pharmaceuticals** · enrollment: 146 (actual)

## Conditions studied

- Iron Deficiency Anemia

## Interventions

- **DRUG:** Sodium Ferric Gluconate Complex
- **DRUG:** Sodium Ferric Gluconate Complex
- **DRUG:** Oral Iron

## Key facts

- **NCT ID:** NCT00223977
- **Lead sponsor:** Watson Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2004-11
- **Final completion:** 2008-02
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2013-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00223977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00223977, "2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00223977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*